Repatha: Additional Ph III GLAGOV data

Additional data from the double-blind, international Phase III GLAGOV trial in 968 CAD patients receiving optimized statin therapy and undergoing coronary catheterization showed that once-monthly 420 mg subcutaneous Repatha reduced

Read the full 307 word article

User Sign In